Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Long-Term Deferred Tax (2016 - 2025)

Haemonetics (HAE) has 16 years of Long-Term Deferred Tax data on record, last reported at $7.3 million in Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax fell 8.39% year-over-year to $7.3 million; the TTM value through Dec 2025 reached $7.3 million, down 8.39%, while the annual FY2025 figure was $7.8 million, 0.83% up from the prior year.
  • Long-Term Deferred Tax reached $7.3 million in Q4 2025 per HAE's latest filing, down from $7.6 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $9.4 million in Q2 2024 and bottomed at $4.3 million in Q4 2022.
  • Average Long-Term Deferred Tax over 5 years is $6.4 million, with a median of $6.1 million recorded in 2021.
  • Peak YoY movement for Long-Term Deferred Tax: decreased 29.39% in 2022, then surged 92.18% in 2024.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $6.1 million in 2021, then decreased by 20.15% to $4.8 million in 2022, then increased by 4.71% to $5.1 million in 2023, then skyrocketed by 57.79% to $8.0 million in 2024, then decreased by 8.39% to $7.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Deferred Tax were $7.3 million in Q4 2025, $7.6 million in Q3 2025, and $7.8 million in Q2 2025.